People with narcolepsy are not only excessively sleepy, but they are also prone to gaining weight. In fact, narcoleptic patients will often pack on pounds even as they eat considerably less than your average person.
Now researchers reporting in the October issue of Cell Metabolism, a Cell Press publication, appear to have an answer as to why. It seems a deficiency of the neuropeptide hormone orexin, an ingredient that encourages hunger and wakefulness, may leave them with a lack of energy-burning brown fat.
The findings may lead to orexin-based weight loss therapies for those with narcolepsy Continue reading →
ST LOUIS – Researchers at Washington University School of Medicine in St. Louis have found a link between sleep loss and increase in Alzheimer’s plaques.
In the study, published in Science Express, researchers found that chronic sleep deprivation in a mouse model of Alzheimer’s disease makes Alzheimer’s brain plaques appear earlier and more often.
They also found that orexin, a protein that helps regulate the sleep cycle, appears to be directly involved in the increase.
Neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease often disrupt sleep.
“Orexin or compounds it interacts with may become new drug targets for treatment of Alzheimer’s disease,” says senior author DavidM.Holtzman, M.D., the Andrew and GretchenJones Professor and chair of the Department of Neurology at the School of Medicine and neurologist-in-chief at Barnes-Jewish Hospital.
“The results also suggest that we may need to prioritize treating sleep disorders not only for their many acute effects but also for potential long-term impacts on brain health,” the expert added.
Holtzman’s laboratory uses a technique called in vivo microdialysis to monitor levels of amyloid beta in the brains of mice genetically engineered as a model of Alzheimer’s disease. Amyloid beta is a protein fragment that is the principal component of Alzheimer’s plaques.
Jae-EunKang, Ph.D., a post-doctoral fellow in Holtzman’s lab, noticed that brain amyloid beta levels in mice rose and fell in association with sleep and wakefulness, increasing in the night, when mice are mostly awake, and decreasing during the day, when they are mostly asleep.
A separate study of amyloid beta levels in human cerebrospinal fluid led by RandallBateman, M.D., assistant professor of neurology and a neurologist at Barnes-Jewish Hospital, also showed that amyloid beta levels were generally higher when subjects were awake and lower when they slept.
To confirm the link, Kang learned to use electroencephalography (EEG) on the mice at the Sleep and Circadian Neurobiology Laboratory at Stanford University with researchers Seiji Nishino, M.D., Ph.D., and NobuhiroFujiki, M.D., Ph.D. The EEG readings let researchers more definitively determine when mice were asleep or awake and validated the connection: Mice that stayed awake longer had higher amyloid beta levels.
“This makes sense in light of an earlier study in our lab where JohnCirrito, Ph.D., showed that increases in synaptic activity resulted in increased levels of amyloid beta,” Holtzman notes.
“The brain’s synapses may generally be more active when we’re awake,” the expert added.
Depriving the mice of sleep caused a 25 percent increase in amyloid beta levels. Levels were lower when mice were allowed to sleep. Blocking a hormone previously linked to stress and amyloid beta production had no effect on these changes, suggesting that they weren’t caused by the stress of sleep deprivation, according to Holtzman.
When Holtzman’s group injected orexin into the brains of the mice, mice stayed awake longer, and amyloid beta levels increased. When researchers used a drug called almorexant to block both orexin receptors, amyloid beta levels were significantly lower and animals were awake less.
Miranda M. Lim, M.D., Ph.D., a neurology resident and post-doctoral researcher in Holtzman’s lab, performed long-term behavioral experiments with the mice. She found that three weeks of chronic sleep deprivation accelerated amyloid plaque deposition in the brain. In contrast, when mice were given almorexant for two months, plaque deposition significantly decreased, dropping by more than 80 percent in some brain regions.
“This suggests the possibility that a treatment like this could be tested to see if it could delay the onset of Alzheimer’s disease,” says Holtzman.